DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8d2dlv/cabozantinib) has announced the addition of GlobalData's new report "Cabozantinib (Prostate Cancer) - Forecast and Market Analysis to 2022" to their offering.
GlobalData has released its new PharmaPoint Drug Evaluation report, Cabozantinib (Prostate Cancer) - Forecast and Market Analysis to 2022. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC.
The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.
Exelixis' cabozantinib is a tyrosine kinase inhibitor of both c-MET and VEGFR-2. Cabozantinib is currently being developed as a second-line therapy for men with mCRPC. It is administered orally once daily at a dose of 100mg. In the Phase II randomized discontinuation trial, the most common Grade 3 or 4 adverse events that participants experienced included fatigue, hand-foot syndrome, hypertension, decreased appetite, nausea, and vomiting. Other reported medical events included hemorrhage, venous thrombosis, gastrointestinal perforation, and arterial thrombosis.
Scope
- Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cabozantinib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cabozantinib for the top nine countries from 2012 to 2022.
- Sales information covered for the US, Japan, UK, France, Germany,Spain, Italy , Canada, and Australia
For more information visit http://www.researchandmarkets.com/research/8d2dlv/cabozantinib
Source: GlobalData